May 2, 2016 | Israeli cancer treatment drug developer Biocancell announced a $6 million financing round from US investors. Biocancell also announced the recruitment of a US CEO: former Ariad senior VP and chief medical officer Frank Haluska. The company also intends to register for trading on the Nasdaq stock exchange and raise tens of millions of dollars there. The company was founded in 2004 by Prof. Avraham Hochberg, a professor of molecular biology at the Hebrew University in Jerusalem.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments